Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
- Registration Number
- NCT00837746
- Lead Sponsor
- Warner Chilcott
- Brief Summary
This study analysed and reported on the study data from three similar, risedronate studies, 1996052, 2003073, and 2003096. The objective of the study was to determine the differences in the iliac crest bone histomorphometry and bone quality in postmenopausal women who had received long term therapy with risedronate.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 29
Inclusion Criteria
- Completed month 36 of Study RVN-008993.
- Underwent an iliac crest bone biopsy at month 36.
Exclusion Criteria
- Was less than 60% compliant with regard to taking study drug from the start of the study drug to month 24 of study RVN-008993.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 risedronate Women taking risedronate for 5 years
- Primary Outcome Measures
Name Time Method Differences in iliac crest bone histomorphometry and bone quality in patients receiving risedronate 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Maria Greenwald, MD
🇺🇸Palm Desert, California, United States
Paul Miller, MD
🇺🇸Lakewood, Colorado, United States
Grattan Woodson, MD
🇺🇸Decatur, Georgia, United States
Christopher Recknor, MD
🇺🇸Gainesville, Georgia, United States
Robert Recker, MD
🇺🇸Omaha, Nebraska, United States
Nelson Watts, MD
🇺🇸Cincinnati, Ohio, United States
Ronald D Emkey, MD
🇺🇸Wyomissing, Pennsylvania, United States
Louis-Georges Ste-Marie, MD
🇨🇦Montreal, Quebec, Canada
Maria Greenwald, MD🇺🇸Palm Desert, California, United States